文献速递乳腺癌

帕妥珠单抗联合曲妥珠单抗双重HER2阻断用于HER2阳性早期乳腺癌:随机III期GeparSepto试验数据亚组分析

Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.
PubMed 文献 · Ann Oncol · 2017-01-01

GeparSepto III期试验的亚组分析纳入396例HER2阳性早期乳腺癌患者,评估帕妥珠单抗联合曲妥珠单抗加化疗的疗效与安全性。HER2阳性组pCR率为57.8%,高于HER2阴性组的22.0%(P<0.0001);HER2阳性/HR阴性亚组pCR率最高达71.0%。HER2阳性组3-4级腹泻和发热性中性粒细胞减少发生率显著高于HER2阴性组。

要点

  • HER2阳性组pCR率57.8% vs HER2阴性组22.0%(P<0.0001)。
  • HER2阳性/HR阴性亚组pCR率最高,为71.0%(Pac 66.7%,nab-Pac 74.6%)。
  • HER2阳性组3-4级腹泻7.6% vs 0.9%(P<0.001)。

核心结论

  • 在HER2阳性早期乳腺癌中,帕妥珠单抗联合曲妥珠单抗双重HER2阻断联合紫杉烷-表柔比星-环磷酰胺新辅助化疗获得高pCR率。

研究设计与样本

  • 随机III期GeparSepto试验的亚组分析,纳入HER2阳性肿瘤患者396例,并与HER2阴性队列比较;总研究人群1206例。
  • 患者接受每周紫杉醇4周期(溶剂型紫杉醇或白蛋白结合型紫杉醇,按随机化分配),随后表柔比星90 mg/m2联合环磷酰胺600 mg/m2每3周1次共4周期;HER2阳性者同步每3周1次曲妥珠单抗和帕妥珠单抗。
  • 主要终点为pCR,定义为ypT0 ypN0。

主要发现

  • HER2阳性组pCR率57.8% vs HER2阴性组22.0%(P<0.0001)。
  • HER2阳性/HR阴性队列pCR率最高,为71.0%(Pac 66.7%,nab-Pac 74.6%)。
  • HER2阳性/HR阳性肿瘤pCR率为52.9%(Pac 49.7%,nab-Pac 56.4%)。
  • HER2阳性组较HER2阴性组3-4级腹泻更常见:7.6% vs 0.9%(P<0.001)。
  • HER2阳性组较HER2阴性组发热性中性粒细胞减少更常见:6.3% vs 3.3%(P=0.023)。

关键数值与推荐

  • pCR定义为ypT0 ypN0。
  • HER2阳性组pCR率57.8% vs HER2阴性组22.0%(P<0.0001)。
  • HER2阳性/HR阴性亚组pCR率71.0%(Pac 66.7%,nab-Pac 74.6%)。
  • HER2阳性/HR阳性亚组pCR率52.9%(Pac 49.7%,nab-Pac 56.4%)。
  • 3-4级腹泻:HER2阳性组7.6% vs HER2阴性组0.9%(P<0.001);发热性中性粒细胞减少:6.3% vs 3.3%(P=0.023)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The neoadjuvant phase III GeparSepto study showed that substituting nab-paclitaxel for standard solvent-based paclitaxel significantly improved the pathologic complete response (pCR) rate achieved with a sequential neoadjuvant chemotherapy regimen of paclitaxel, epirubicin, and cyclophosphamide for high-risk primary breast cancer. Recent trials demonstrated that in HER2+ breast cancer pCR can be increased by using pertuzumab in addition to trastuzumab and chemotherapy. The present analysis focuses on efficacy and safety data from the subset of patients with HER2+ tumors from the GeparSepto trial (n = 396) in comparison to the HER2- cohort. PATIENTS AND METHODS: Patients with histologically confirmed breast cancer (n = 1206) received four cycles of weekly paclitaxel [either solvent-based (Pac) or nab-paclitaxel (nab-Pac), according to randomization] followed by 4 cycles of epirubicin 90 mg/m2 plus cyclophosphamide 600 mg/m2 q3w, with concurrent trastuzumab and pertuzumab q3w for those with HER2+ tumors. The primary endpoint was pCR defined as ypT0 ypN0. RESULTS: Higher rates of pCR were achieved in HER2+ than in HER2- tumors (57.8% versus 22.0%, P < 0.0001), with the highest rate in the HER2+/HR- cohort (71.0%; 66.7% Pac, 74.6% nab-Pac). In HER2+/HR+ tumors, the pCR rate was 52.9% (49.7% Pac, 56.4% nab-Pac). Grade ≥3 toxic effects were significantly more common in HER2+ than in HER2- patients, with grade 3-4 diarrhea in 7.6% versus 0.9% (P < 0.001) and febrile neutropenia in 6.3% versus 3.3% (P = 0.023) of patients. Left ventricular ejection fraction decreases from baseline were uncommon, with 2.0% versus 0.4% of patients showing decreases to <50% along with a ≥10% decrease from baseline. CONCLUSION: In HER2+ early breast cancer, a dual HER2-targeted combination of pertuzumab and trastuzumab, together with taxane-epirubicin-cyclophosphamide neoadjuvant chemotherapy, achieved high rates of pCR.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Loibl S, Jackisch C, Schneeweiss A, et al. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial. Ann Oncol. 2017. PMID: 27831502. doi:10.1093/annonc/mdw610

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。